Legend Biotech Corporation (NASDAQ: LEGN) is a Healthcare company in the Biotechnology industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.
| Index | - | P/E | - | EPS (ttm) | -0.51 | Insider Own | 0.79% | Shs Outstand | 184.94M | Perf Week | -8.39% |
| Market Cap | 3.25B | Forward P/E | 29.49 | EPS next Y | 0.60 | Insider Trans | -1.47% | Shs Float | 178.18M | Perf Month | -19.80% |
| Enterprise Value | 2.56B | PEG | - | EPS next Q | 0.02 | Inst Own | - | Short Float | 9.25% | Perf Quarter | -47.55% |
| Income | -92.00M | P/S | 2.56 | EPS this Y | 96.84% | Inst Trans | - | Short Ratio | 6.06 | Perf Half Y | -3.46% |
| Sales | 1.27B | P/B | 2.64 | EPS next Y | 3802.69% | ROA | -5.23% | Short Interest | 16.48M | Perf YTD | -19.14% |
| Book/sh | 6.65 | P/C | 3.37 | EPS next 5Y | - | ROE | -8.70% | 52W High | 37.50 -53.12% | Perf Year | -48.81% |
| Cash/sh | 5.22 | P/FCF | - | EPS past 3/5Y | - | ROIC | -3.71% | 52W Low | 16.24 8.25% | Perf 3Y | -73.62% |
| Dividend Est. | - | EV/EBITDA | - | Sales past 3/5Y | 106.42% 68.84% | Gross Margin | 56.58% | Volatility | 5.11% 4.67% | Perf 5Y | -53.37% |
| Dividend TTM | - | EV/Sales | 2.02 | EPS Y/Y TTM | 47.42% | Oper. Margin | -4.42% | ATR (14) | 1.01 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 2.94 | Sales Y/Y TTM | 102.71% | Profit Margin | -7.21% | RSI (14) | 33.89 | Recom | 2.25 |
| Dividend Gr. 3/5Y | - | Current Ratio | 3.04 | EPS Q/Q | 126.47% | SMA20 | -12.64% | Beta | 0.58 | Target Price | 56.14 |
| Payout | 0.00% | Debt/Eq | 0.41 | Sales Q/Q | 52.16% | SMA50 | -16.55% | Rel Volume | 0.78 | Prev Close | 17.00 |
| Employees | 3,200 | LT Debt/Eq | 0.09 | Earnings | Nov 11 | SMA200 | -22.77% | Avg Volume | 2.49M | Price | 17.58 |
| IPO Date | Jun 05, 2020 | Option/Short | Yes / Yes | EPS/Sales Surpr. | 59.94% 8.86% | Net Debt/EBITDA | 54.49 | Volume | 1,952,280 | Change | 3.41% |
| Date | Action | Analyst | Rating | Target |
|---|---|---|---|---|
| Sep-04-26 | Reiterated | Morgan Stanley | Overweight | $48 → $65 |
| Aug-12-26 | Downgrade | Oppenheimer | Outperform → Perform | $40 |
| Aug-12-26 | Reiterated | Barclays | Overweight | |
| Jul-27-26 | Reiterated | Raymond James | $58 | |
| Jul-27-26 | Reiterated | RBC Capital | Outperform | $63 → $59 |
| Jul-24-26 | Downgrade | UBS | Buy → Neutral | $49 → $28 |
| Jul-07-26 | Reiterated | RBC Capital | Outperform | $64 → $63 |
| Jun-03-26 | Reiterated | UBS | Buy | $50 → $49 |
| Jun-03-26 | Reiterated | HC Wainwright & Co. | Buy | $50 → $65 |
| Jun-01-26 | Reiterated | UBS | Buy | $48 → $50 |
Legend Biotech Corporation, through its subsidiaries, operates as a biopharmaceutical company that discovers, develops, manufactures, and commercializes novel cell therapies for oncology and other indications in the United States, China, and Europe. Its lead product candidate is ciltacabtagene autoleucel, or cilta-cel, which is a chimeric antigen receptor (CAR-T) therapy for the treatment of multiple myeloma (MM). The company also has a portfolio of earlier-stage autologous CAR-T product candidates targeting various cancers, including acute lymphoblastic leukemia, gastric cancer, esophageal cancer, pancreatic cancer, colorectal cancer, small cell lung cancer, and non-small cell lung cancer. In addition, it develops allogeneic gamma delta CAR-T and allogeneic CAR-NK product candidates targeting B-cell maturation antigen (BCMA) for MM, which are in investigator-initiated Phase 1 clinical trials in China. The company has a collaboration and license agreement with Janssen Biotech, Inc. for the development and commercialization of cilta-cel, as well as a license agreement with Novartis Pharma AG for the development, manufacture, and commercialization of CAR-T cell therapies targeting delta-like ligand protein 3. Legend Biotech Corporation was founded in 2014 and is headquartered in Somerset, New Jersey.
Per-holder 13F data hasn't been ingested for this ticker yet.
| Line Item (USD, M) | TTM — | FY 2025 12/31/2025 | FY 2024 12/31/2024 | FY 2023 12/31/2023 | FY 2022 12/31/2022 | FY 2021 12/31/2021 | FY 2020 12/31/2020 | FY 2019 12/31/2019 | FY 2018 12/31/2018 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 1,271 | 1,029 | 627 | — | — | — | — | — | — | |
| Cost of Goods Sold Incl. D&A | 551 | 408 | 235 | — | — | — | — | — | — | |
| Gross Profit | 719 | 621 | 393 | — | — | — | — | — | — | |
| Selling, General and Administrative Excl. Other | 374 | 342 | 284 | — | — | — | — | — | — | |
| Research and Development | 396 | 415 | 414 | — | — | — | — | — | — | |
| Other Operating Expense | 5 | 0 | -2 | — | — | — | — | — | — | |
| Operating Income | -56 | -136 | -303 | — | — | — | — | — | — | |
| Interest Expense | 17 | 21 | 22 | — | — | — | — | — | — | |
| Unusual Expense | — | — | — | — | — | — | — | — | — | |
| Non-Operating Income (Expense) | 16 | -125 | 167 | — | — | — | — | — | — | |
| Net Income Before Taxes | -56 | -283 | -158 | — | — | — | — | — | — | |
| Income Taxes | 35 | 14 | 19 | — | — | — | — | — | — | |
| Consolidated Net Income | -92 | -297 | -177 | — | — | — | — | — | — | |
| Net Income From Continuing Operations | -92 | -297 | -177 | — | — | — | — | — | — | |
| Net Income | -92 | -297 | -177 | — | — | — | — | — | — | |
| EPS (Recurring) | -0.50 | -1.60 | -0.97 | — | — | — | — | — | — | |
| EPS (Basic, Before Extraordinaries) | -0.50 | -1.60 | -0.97 | — | — | — | — | — | — | |
| EPS (Diluted) | -0.51 | -1.60 | -0.97 | — | — | — | — | — | — | |
| EBITDA | -7 | -232 | -113 | — | — | — | — | — | — | |
| Other After Tax Adjustments | — | — | — | — | — | — | — | — | — | |
| Stock Option Compensation Expense | — | — | — | — | — | — | — | — | — | |
| Price To Earnings Ratio | — | — | — | — | — | — | — | — | — | |
| Price To Sales Ratio | 2.59 | 3.89 | 9.50 | — | — | — | — | — | — | |
| Gross Margin | 56.57 | 60.35 | 62.68 | — | — | — | — | — | — | |
| Operating Margin | -4.41 | -13.22 | -48.33 | — | — | — | — | — | — | |
| Net Margin | -7.24 | -28.86 | -28.23 | — | — | — | — | — | — | |
| Shares Outstanding | 187 | 184 | 183 | — | — | — | — | — | — | |
| Market Capitalization | 3,287 | 4,000 | 5,955 | — | — | — | — | — | — | |
| Operating Lease Expense | — | — | — | — | — | — | — | — | — |
| Insider | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Casey Patrick John | Director | Jun 30 '26 | Sale | 14.80 | 6,000 | 88,800 | 48,604 | Jul 02 |
| Huang Ying | Chief Executive Officer | Jun 25 '26 | Sale | 14.78 | 5,566 | 82,265 | 241,872 | Jun 29 |
| Huang Ying | Chief Executive Officer | Mar 25 '26 | Sale | 8.77 | 9,936 | 87,139 | 247,438 | Mar 27 |